Feature | Stents | May 16, 2016

Cordis Returns to Drug-eluting Stent Market

Cardinal Health signs distribution agreement with Biosensors to expand Cordis’ cardiovascular product offering 

Biosensors' Biomatrix stent.

May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables Cordis, Cardinal Health’s interventional vascular business, to sell Biosensors’ coronary stent portfolio. Cordis will sell Biosensors’ coronary stents in select countries in Europe, the Middle East, Africa, Australia and New Zealand. This marks Cordis’ return to the drug-eluting stent (DES) market and the beginning of a long-term partnership between Cardinal Health and Biosensors to further leverage their respective distribution capabilities in select regions. 

Cordis will now offer an expanded portfolio of products in select countries to further support the treatment of patients undergoing percutaneous coronary intervention (PCI), from access to intervention and closure. PCI is a nonsurgical procedure that often uses a catheter to place a stent to open blocked coronary arteries caused by coronary artery disease. Coronary artery disease is the most common type of heart disease and is expected to continue to be the leading cause of death globally for the next 20 years. 

“We are very excited about this DES agreement with Biosensors, because it represents our strong commitment to expand our product portfolio to support the demands in cardiovascular care today,” said David Wilson, president of Cordis, a Cardinal Health company. “While Cordis is known for developing product innovations, partnerships like this provide an opportunity to rapidly expand our unmatched portfolio and deliver increased value to customers and the patients they serve.” 

In the next few months, Cordis will begin offering Biosensors’ coronary stent portfolio, which includes the BioFreedom polymer-free drug-coated stent; the BioMatrix NeoFlex DES; BioMatrix Alpha, a cobalt chromium DES with an abluminal bio-absorbable coating; and the Chroma cobalt chromium bare metal stent (BMS), in select European countries, Australia and New Zealand. Over time, Cordis will begin to sell these products under the Lumeno private label in select countries, and both companies will continue to leverage their respective distribution capabilities in additional European countries, the Middle East, Africa and other parts of the world. 

Biosensors’ DES with a bio-absorbable coating and the Biolimus A9 drug are supported by multiple large-scale studies, including data from LEADERS, a prospective, randomized, multi-center clinical trial that demonstrated that the safety and efficacy of Biosensors’ BioMatrix Flex stent is comparable to that of a durable polymer DES in a population of 1,707 patients across 10 European centers. Additionally, data published in the New England Journal of Medicine from LEADERS FREE — the first prospective, double-blind, randomized clinical trial exclusively focusing on patients at high-bleeding risk receiving only one month of dual anti-platelet therapy (DAPT) — demonstrated superiority with respect to the primary safety and efficacy endpoints for BioFreedom as compared to a BMS in patients undergoing PCI. The trial assessed the shortest course of DAPT ever used with an active stent. LEADERS FREE included 2,466 patients across 68 sites in 20 countries in Europe, Asia, Australia and Canada, with a follow-up phase of two years.

Biosensors’ coronary stents have not been approved by the U.S. Food and Drug Administration and are not commercially available in the United States.

For more information: www.cordis.com

 

 

Related Content

The Current Direction of Healthcare Reform Explained by CMS Administrator Seema Verma
News | Cardiovascular Business | June 11, 2019
Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma addressed the American Medical Association (...
DAIC Earns Azbee National Bronze Award for Social Media Presence
News | Cardiovascular Business | May 10, 2019
May 10, 2019 — Diagnostic and Interventional Cardiology (DAIC) earned a Bronze Award at the 2019 Na
Cath lab staff working as a team to prepare for a procedure at Presbyterian Medical Center Cardiac Cath Lab, Charlotte N.C. Pictured are Barry Horsey RCIS, Emily Luna RN, RCIS, Adam Martin RCIS, Caleadia Jessup RN.

Cath lab staff working as a team to prepare for a procedure at Presbyterian Medical Center Cardiac Cath Lab, Charlotte N.C. Pictured are Barry Horsey RCIS, Emily Luna, RN, RCIS, Adam Martin, RCIS, Caleadia Jessup, RN.

Feature | Cardiovascular Business | May 03, 2019 | Ruben Filimonczuk, RCES, AS-PMD
One of the most promising areas for innovation in healthcare is to be found in the workforce – both in hiring and ret
Fail-safe Program for New Medical Technology Focuses on Patient Safety
News | Cardiovascular Business | April 29, 2019
New medical technology offers the promise of improving patient care, as well as the potential for harm if caregivers...
Medicare Trustees Report Hospital Insurance Trust Fund Will Deplete in Seven Years
News | Cardiovascular Business | April 22, 2019
The Medicare Hospital Insurance (HI) Trust Fund, which funds Medicare Part A, will only be able to pay full benefits...
Videos | Cardiovascular Business | April 16, 2019
A discussion with Ruth Fisher, MBA, vice president of the...
Foreign-trained doctors now make up one-third of cardiologists in the United States and help make up for the U.S. overall shortage of physicians. Pictured here is co-author of this article Mandeep R. Mehra, MBBS, MSc, FRCP, who is an example of the contribution international physicians have made in the U.S. He is medical director of the Brigham and Women’s Hospital Heart and Vascular Center.

Foreign-trained doctors now make up one-third of cardiologists in the United States and help make up for the overall shortage of physicians. Pictured here is co-author of this article Mandeep R. Mehra, MBBS, MSc, FRCP, who is an example of the contribution international physicians have made in the U.S. He is medical director of the Brigham and Women’s Hospital Heart and Vascular Center, The William Harvey Distinguished Chair in Advanced Cardiovascular Medicine, and a professor of medicine at Harvard Medical School. He is past-president of both the Heart Failure Society of America and the International Society of Heart and Lung Transplantation. 

Feature | Cardiovascular Business | April 15, 2019 | William W. Pinsky, M.D., FAAP, FACC, and Mandeep R. Mehra, MBBS, MSc , FRCP
As we strive to process today’s successive news cycles involving negative reports about immigration, it is easy for m
ACC Combines NCDR, Accreditation Into New Quality Summit
News | Cardiovascular Business | March 15, 2019
The American College of Cardiology’s first annual ACC Quality Summit, held March 13-15 in New Orleans, merges the NCDR...
Diagnostic and Interventional Cardiology Named 2019 Azbee Awards Finalist for Social Media
News | Cardiovascular Business | March 08, 2019 | Jeff Zagoudis, Associate Editor
Diagnostic and Interventional Cardiology (DAIC) was named a finalist in the Social Media Presence category for the 2019...
Overlay Init